Investing in ways to improve the diagnosis gap and improve survival rates.”
At Janssen, we are committed to addressing the diagnostic gap and improving survival rates. We have undertaken extensive research to map out the patient journey in pulmonary arterial hypertension (PAH), which allows us to understand the barriers that delay diagnosis and generate strategies to address them.
We are driving innovative research to understand the diagnostic gap, with our colleagues around the world sharing ground-breaking science and development techniques. To continue to grow and enhance our knowledge, we have also entered into several strategic partnerships. For example, we are collaborating with a leading digital health company to investigate the use of diagnostic imaging technology in pulmonary hypertension (PH).
We have also partnered with a world-leading in-vitro diagnostic (IVD) developer, to use machine learning to demonstrate feasibility of developing microRNA-based biomarker signatures to differentiate patients with and without PH. From this, we are now looking at harnessing these miRNA signatures for the development of non-invasive tests that would allow earlier diagnosis of PH.
With our combined skills and resources, we have a clear strategy to maximize the clinical benefit of our current portfolio, close the diagnosis gap and build an innovative pipeline focusing on novel disease-modifying pathways.